SE420718B - Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet - Google Patents

Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet

Info

Publication number
SE420718B
SE420718B SE7502520A SE7502520A SE420718B SE 420718 B SE420718 B SE 420718B SE 7502520 A SE7502520 A SE 7502520A SE 7502520 A SE7502520 A SE 7502520A SE 420718 B SE420718 B SE 420718B
Authority
SE
Sweden
Prior art keywords
decapeptidamide
ovalation
derivatives
inducing activity
make new
Prior art date
Application number
SE7502520A
Other languages
English (en)
Swedish (sv)
Other versions
SE7502520L (nl
Inventor
M Fujino
T Fukuda
S Shinagawa
Original Assignee
Takeda Chemical Industries Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Chemical Industries Ltd filed Critical Takeda Chemical Industries Ltd
Publication of SE7502520L publication Critical patent/SE7502520L/xx
Publication of SE420718B publication Critical patent/SE420718B/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10Tetrapeptides
    • C07K5/1002Tetrapeptides with the first amino acid being neutral
    • C07K5/1005Tetrapeptides with the first amino acid being neutral and aliphatic
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04Linear peptides containing only normal peptide links
    • C07K7/23Luteinising hormone-releasing hormone [LHRH]; Related peptides
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10STECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S930/00Peptide or protein sequence
    • Y10S930/01Peptide or protein sequence
    • Y10S930/13Luteinizing hormone-releasing hormone; related peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SE7502520A 1974-03-08 1975-03-06 Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet SE420718B (sv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2744274A JPS5726506B2 (nl) 1974-03-08 1974-03-08

Publications (2)

Publication Number Publication Date
SE7502520L SE7502520L (nl) 1975-09-09
SE420718B true SE420718B (sv) 1981-10-26

Family

ID=12221217

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7502520A SE420718B (sv) 1974-03-08 1975-03-06 Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet

Country Status (18)

Country Link
US (1) US3972859A (nl)
JP (1) JPS5726506B2 (nl)
AT (1) AT348693B (nl)
BE (1) BE826430A (nl)
CA (1) CA1072953A (nl)
CH (1) CH615661A5 (nl)
CS (1) CS186284B2 (nl)
DE (1) DE2509783C2 (nl)
DK (1) DK149862C (nl)
ES (1) ES435405A1 (nl)
FI (1) FI60859C (nl)
FR (1) FR2262995B1 (nl)
GB (1) GB1498048A (nl)
HU (1) HU174077B (nl)
NL (1) NL181658C (nl)
NO (1) NO145691C (nl)
SE (1) SE420718B (nl)
ZA (1) ZA751306B (nl)

Families Citing this family (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2438350C3 (de) * 1974-08-09 1979-06-13 Hoechst Ag, 6000 Frankfurt Peptide mit starker LH-RH/FSH-RH-Wirkung, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zubereitungen
AU497512B2 (en) * 1975-04-15 1978-12-14 Ici Australia Limited Nona and deca-peptides
US4215038A (en) * 1978-10-16 1980-07-29 The Salk Institute For Biological Studies Peptides which inhibit gonadal function
US4234571A (en) * 1979-06-11 1980-11-18 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide derivatives of luteinizing hormone releasing hormone
US4318905A (en) * 1980-06-23 1982-03-09 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide agonists of luteinizing hormone releasing hormone containing heterocyclic amino acid residues
ZA815447B (en) * 1980-08-29 1982-08-25 Salk Inst For Biological Studi Peptides affecting gonadal function
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4675189A (en) * 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
IE52535B1 (en) * 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
JPS58501861A (ja) * 1981-12-28 1983-11-04 ベツクマン・インストルメンツ・インコ−ポレ−テツド 下垂体成長ホルモン放出活性を有する合成ペプチド
JPS58125819U (ja) * 1982-02-19 1983-08-26 名伸電機株式会社 積算電力量計用パツキン
US4667014A (en) * 1983-03-07 1987-05-19 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH antagonists
US4481190A (en) * 1982-12-21 1984-11-06 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH useful as LHRH antagonists
US4581169A (en) * 1982-12-21 1986-04-08 Syntex (U.S.A.) Inc. Nona-peptide and deca-peptide analogs of LHRH, useful as LHRH antagonists
US4663435A (en) * 1982-12-06 1987-05-05 Merck & Co., Inc. Bridged cyclic hexapeptide somatostatin analogs
US4581168A (en) * 1983-02-21 1986-04-08 Sanofi Synthesis of hpGRF (Somatocrinin) in liquid phase and intermediate peptides
US4530920A (en) * 1983-11-07 1985-07-23 Syntex (U.S.A.) Inc. Nonapeptide and decapeptide analogs of LHRH, useful as LHRH agonist
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JP2653255B2 (ja) 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
CA2050425A1 (en) 1990-09-03 1992-03-04 Yoshiaki Uda Pharmaceutical composition and its mucous use
NZ240214A (en) 1990-10-16 1993-02-25 Takeda Chemical Industries Ltd Polymer compositions comprising a polylactic acid and a copolymer of glycolic acid and a hydroxycarboxylic acid; use as carrier for prolonged release pharmaceutical compositions of water soluble drugs
US6031003A (en) * 1991-08-23 2000-02-29 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6313146B1 (en) 1991-08-23 2001-11-06 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US6011068A (en) * 1991-08-23 2000-01-04 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US5688938A (en) * 1991-08-23 1997-11-18 The Brigham & Women's Hospital, Inc. Calcium receptor-active molecules
US5763569A (en) * 1991-08-23 1998-06-09 The Brigham And Women's Hospital, Inc Calcium receptor-active molecules
US5518730A (en) * 1992-06-03 1996-05-21 Fuisz Technologies Ltd. Biodegradable controlled release flash flow melt-spun delivery system
ATE161716T1 (de) 1992-08-07 1998-01-15 Takeda Chemical Industries Ltd Herstellung von mikrokapseln, die wasserlösliche arzneimittel enthalten
US5962314A (en) * 1993-02-23 1999-10-05 Nps Pharmaceuticals, Inc. Calcium receptor-active molecules
US20040259113A1 (en) * 1993-07-22 2004-12-23 Mayo Foundation For Medical Education And Research, Hybritech Incorporated Method for detection of metastatic prostate cancer
US6103237A (en) * 1993-07-22 2000-08-15 Hybritech Incorporated Stable variant hK2 polypeptide
US5516639A (en) * 1993-07-22 1996-05-14 Mayo Foundation For Medical Education And Research Antibodies specific for human prostate glandular kallkrein
US5594091A (en) * 1994-02-21 1997-01-14 Takeda Chemical Industries, Ltd. Matrix for sustained-release preparation
CA2189774A1 (en) * 1994-05-10 1995-11-16 Donald J. Tindall Recombinant hk2 polypeptide
US6117455A (en) * 1994-09-30 2000-09-12 Takeda Chemical Industries, Ltd. Sustained-release microcapsule of amorphous water-soluble pharmaceutical active agent
CZ290670B6 (cs) 1994-10-21 2002-09-11 Nps Pharmaceuticals, Inc. Sloučeniny modulující receptory anorganických iontů a farmaceutický prostředek, který je obsahuje
US5837281A (en) 1995-03-17 1998-11-17 Takeda Chemical Industries, Ltd. Stabilized interface for iontophoresis
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
CA2192773C (en) 1995-12-15 2008-09-23 Hiroaki Okada Production of sustained-release preparation for injection
PT907631E (pt) * 1996-05-01 2003-10-31 Nps Pharma Inc Compostos inorganicos activos como receptores de ioes
EP0813887A3 (en) * 1996-06-20 1999-11-03 Hisamitsu Pharmaceutical Co. Inc. A device structure for iontophoresis
US6479263B1 (en) 1996-11-14 2002-11-12 Baylor College Of Medicine Method for detection of micrometastatic prostate cancer
WO1998059073A1 (en) 1997-06-20 1998-12-30 Mayo Foundation For Medical Education And Research Method for detection of breast cancer
US6737408B1 (en) 1997-08-07 2004-05-18 University Of Cincinnati Compounds for control of appetite, blood pressure, cardiovascular response, libido, and circadian rhythm
US6087128A (en) 1998-02-12 2000-07-11 Ndsu Research Foundation DNA encoding an avian E. coli iss
US8609614B2 (en) * 1998-07-22 2013-12-17 Vanderbilt University GBS toxin receptor compositions and methods of use
US6803448B1 (en) * 1998-07-22 2004-10-12 Vanderbilt University GBS toxin receptor
US6339062B1 (en) 1998-11-23 2002-01-15 Inkine Pharmaceutical Company, Inc. Retroinverso polypeptides that mimic or inhibit thrombospondin activity
US20040241842A1 (en) * 1999-04-15 2004-12-02 Monash University Stimulation of thymus for vaccination development
US20050042679A1 (en) * 1999-04-15 2005-02-24 Monash University Diagnostic indicator of thymic function
US20040259803A1 (en) * 1999-04-15 2004-12-23 Monash University Disease prevention by reactivation of the thymus
US20040258672A1 (en) * 1999-04-15 2004-12-23 Monash University Graft acceptance through manipulation of thymic regeneration
AUPR074500A0 (en) * 2000-10-13 2000-11-09 Monash University Treatment of t cell disorders
US20040265285A1 (en) * 1999-04-15 2004-12-30 Monash University Normalization of defective T cell responsiveness through manipulation of thymic regeneration
US20050020524A1 (en) * 1999-04-15 2005-01-27 Monash University Hematopoietic stem cell gene therapy
US20070274946A1 (en) * 1999-04-15 2007-11-29 Norwood Immunoloty, Ltd. Tolerance to Graft Prior to Thymic Reactivation
JP2003512303A (ja) * 1999-08-06 2003-04-02 ジェネンテック・インコーポレーテッド 因子viiaのペプチドアンタゴニスト
US6407211B1 (en) * 1999-12-17 2002-06-18 Mayo Foundation For Medical Education And Research Chimeric natriuretic peptides
US20040001827A1 (en) * 2002-06-28 2004-01-01 Dennis Mark S. Serum albumin binding peptides for tumor targeting
EP1757701A1 (en) 1999-12-24 2007-02-28 Genentech, Inc. Methods and compositions for prolonging elimination half-times of bioactive compounds
US20060228364A1 (en) * 1999-12-24 2006-10-12 Genentech, Inc. Serum albumin binding peptides for tumor targeting
PT1240337E (pt) 1999-12-24 2007-01-31 Genentech Inc Métodos e composições para prolongar as meias-vidas de eliminação de compostos bioactivos
US20050287153A1 (en) * 2002-06-28 2005-12-29 Genentech, Inc. Serum albumin binding peptides for tumor targeting
US20060088512A1 (en) * 2001-10-15 2006-04-27 Monash University Treatment of T cell disorders
US7164002B2 (en) 2002-02-06 2007-01-16 Genentech, Inc. FVIIa antagonists
WO2005018682A2 (en) 2003-08-20 2005-03-03 The Regents Of The University Of California Somatostatin analogs with inhibitory activity to growth hormone release
US7790855B2 (en) * 2003-09-18 2010-09-07 Macrogenics, Inc. KID3 and KID3 antibodies that bind thereto
US20080279812A1 (en) * 2003-12-05 2008-11-13 Norwood Immunology, Ltd. Disease Prevention and Vaccination Prior to Thymic Reactivation
JP4390568B2 (ja) * 2004-01-19 2009-12-24 富士通株式会社 遅延測定システム
CA2569692C (en) * 2004-06-07 2015-07-21 Raven Biotechnologies, Inc. Transferrin receptor antibodies
BRPI0516577A (pt) * 2004-10-05 2008-09-16 Genentech Inc agentes terapêuticos com toxicidade diminuìda
EP1846767B1 (en) * 2005-01-12 2012-06-06 MacroGenics West, Inc. Kid31 and antibodies that bind thereto
US7847070B2 (en) * 2005-01-31 2010-12-07 Raven Biotechnologies, Inc. LUCA2 and antibodies that bind thereto
WO2006084078A2 (en) * 2005-02-02 2006-08-10 Raven Biotechnologies, Inc. Jam-3 and antibodies that bind thereto
CA2596273C (en) 2005-02-02 2017-11-14 Raven Biotechnologies, Inc. Adam-9 modulators
JP5328156B2 (ja) 2005-02-03 2013-10-30 マクロジェニックス ウエスト, インコーポレイテッド オンコスタチンmレセプターに対する抗体
EP1790656A1 (en) * 2005-11-25 2007-05-30 Nanokem S.A. Solution-phase synthesis of leuprolide
US20070197445A1 (en) * 2006-01-18 2007-08-23 University Of Cincinnati Compounds for control of appetite
JP5601836B2 (ja) 2006-11-08 2014-10-08 マクロジェニックス ウエスト, インコーポレイテッド Tes7およびtes7に結合する抗体
WO2010123946A2 (en) 2009-04-20 2010-10-28 Allergan, Inc. Silk fibroin hydrogels and uses thereof
PL219569B1 (pl) * 2010-02-19 2015-05-29 Peptaderm Spółka Z Ograniczoną Odpowiedzialnością Cykliczne tetrapeptydy i ich zastosowanie
US8802091B2 (en) 2010-03-04 2014-08-12 Macrogenics, Inc. Antibodies reactive with B7-H3 and uses thereof
GEP201706660B (en) 2010-03-04 2017-04-25 Macrogenics Inc Antibodies reactive with b7-h3, immunologically active fragments thereof and uses thereof
BR122016016837A2 (pt) 2011-05-21 2019-08-27 Macrogenics Inc moléculas de ligação a cd3; anticorpos de ligação a cd3; composições farmacêuticas; e usos da molécula de ligação a cd3
EP2557163A1 (en) 2011-08-12 2013-02-13 SymbioGruppe GmbH & Co KG Bacterially formed microcin S, a new antimicrobial peptide, effective against pathogenic microorganisms, e.g. enterohemorrhagic Escherichia coli (EHEC)
PT2748182T (pt) 2011-08-23 2017-01-20 Harvard College Nanopartículas peptídicas e utilizações das mesmas
WO2013032784A1 (en) 2011-08-30 2013-03-07 Mayo Foundation For Medical Education And Research Natriuretic polypeptides
US9611305B2 (en) 2012-01-06 2017-04-04 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US9487587B2 (en) 2013-03-05 2016-11-08 Macrogenics, Inc. Bispecific molecules that are immunoreactive with immune effector cells of a companion animal that express an activating receptor and cells that express B7-H3 and uses thereof
PL2968520T3 (pl) 2013-03-14 2022-01-03 Macrogenics, Inc. Dwuspecyficzne cząsteczki, które są immunoreaktywne wobec immunologicznych komórek efektorowych wykazujących ekspresję receptora aktywującego
CA2911613A1 (en) 2013-03-29 2014-10-02 Centre National De La Recherche Scientifique (Cnrs) Cgrp receptor agonist for hiv treatment or prevention
TWI742423B (zh) 2014-05-29 2021-10-11 美商宏觀基因股份有限公司 特異性結合多種癌症抗原的三特異性結合分子和其使用方法
CA2963991A1 (en) 2014-09-29 2016-04-07 Duke University Bispecific molecules comprising an hiv-1 envelope targeting arm
TWI773646B (zh) 2015-06-08 2022-08-11 美商宏觀基因股份有限公司 結合lag-3的分子和其使用方法
PL3328419T3 (pl) 2015-07-30 2021-12-27 Macrogenics, Inc. Cząsteczki wiążące pd-1 i sposoby ich zastosowania
RU2731202C2 (ru) 2015-10-08 2020-08-31 Макродженикс, Инк. Комбинированная терапия для лечения рака
KR20180100122A (ko) 2015-12-02 2018-09-07 주식회사 에스티사이언스 당화된 btla(b- 및 t-림프구 약화인자)에 특이적인 항체
KR102424513B1 (ko) 2015-12-14 2022-07-25 마크로제닉스, 인크. Pd-1 및 ctla-4과의 면역반응성을 가진 이중특이적 분자, 및 이것의 사용 방법
MX2018012433A (es) 2016-04-15 2019-03-01 Macrogenics Inc Moleculas de union b7-h3 novedosas, conjugados anticuerpo-farmaco de los mismos y metodos de uso de los mismos.
US10111929B1 (en) 2017-04-07 2018-10-30 Ez Ip, Llc Growth hormone releasing factor analogs and uses
JP2022549504A (ja) 2019-09-26 2022-11-25 エスティーキューブ アンド カンパニー グリコシル化ctla-4に対して特異的な抗体およびその使用方法
WO2021072277A1 (en) 2019-10-09 2021-04-15 Stcube & Co. Antibodies specific to glycosylated lag3 and methods of use thereof
US11596665B2 (en) 2020-06-23 2023-03-07 Chanda Zaveri Skin lightening formulations
US11951203B2 (en) 2020-08-26 2024-04-09 Chanda Zaveri Deep wrinkle vanishing compositions
US11793746B2 (en) 2020-10-01 2023-10-24 Chanda Zaveri Intense skin hydration systems and methods
US20220110852A1 (en) 2020-10-14 2022-04-14 Chanda Zaveri Pigment Stabilizers

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3835108A (en) * 1972-02-15 1974-09-10 American Home Prod Process for preparing the releasing hormone of luteinizing hormone(lh)and of follicle stimulating hormone(fsh),salts and compositions thereof,and intermediates therefor
US3896104A (en) * 1974-05-22 1975-07-22 American Home Prod P-glu-his-trp-ser-tyr-d-lys-leu-arg-pro-gly-nh' 2 'and intermediates

Also Published As

Publication number Publication date
FI750682A (nl) 1975-09-09
JPS50121277A (nl) 1975-09-23
CH615661A5 (nl) 1980-02-15
DK149862C (da) 1987-06-15
FR2262995B1 (nl) 1978-07-28
FI60859B (fi) 1981-12-31
HU174077B (hu) 1979-10-28
DE2509783C2 (de) 1983-02-17
CS186284B2 (en) 1978-11-30
DK92775A (nl) 1975-09-09
FR2262995A1 (nl) 1975-10-03
AT348693B (de) 1979-02-26
DK149862B (da) 1986-10-13
ZA751306B (en) 1976-01-28
NL7502564A (nl) 1975-09-10
DE2509783A1 (de) 1975-09-11
SE7502520L (nl) 1975-09-09
NL181658C (nl) 1987-10-01
AU7859475A (en) 1976-08-26
BE826430A (fr) 1975-09-08
JPS5726506B2 (nl) 1982-06-04
NL181658B (nl) 1987-05-04
ATA138075A (de) 1978-07-15
ES435405A1 (es) 1976-12-01
NO750763L (nl) 1975-09-09
US3972859A (en) 1976-08-03
FI60859C (fi) 1982-04-13
NO145691C (no) 1982-05-12
CA1072953A (en) 1980-03-04
NO145691B (no) 1982-02-01
GB1498048A (en) 1978-01-18

Similar Documents

Publication Publication Date Title
SE420718B (sv) Sett att framstella nya dekapeptidamidderivat med ovalationsinducerande aktivitet
SE420717B (sv) Sett att framstella nya nonapeptidamidderivat med ovulationsinducerande aktivitet
SE397520B (sv) Sett att framstella nya nonapeptidamidderivat med ovulationsinducerande aktivitet
SE401822B (sv) Sett att framstella nya nonapeptidamidderivat med ovulationsinducerande aktivitet
SE7508101L (sv) Sett att framstella nya kinazolinderivat med terapeutisk verkan.
SE425244B (sv) Sett att framstella 4-hydroxi-3-kinolin-karboxamidderivat
SE7711848L (sv) Sett att framstella nya 5-metyl-7-hydroxi-isoflavonderivat
SE410600B (sv) Sett att framstella nya arylaminopyrimidinderivat
SE427108B (sv) Sett att framstella nya substituerade fenylettiksyror med inflammationshemmande verkan
SE408300B (sv) Sett att framstella nya dipeptidderivat
SE417507B (sv) Sett att framstella 2-arylamino-2-imidazolinderivat
SE7505974L (sv) Nya foreningar med ergolinskelett jemte sett att framstella dem
SE7602729L (sv) Sett att framstella nya indolylalkylpiperidiner
SE420602B (sv) Sett att framstella pyrazin-3-metoxi-2-karboxamidderivat
SE7511328L (sv) Sett att framstella nya pyridinderivat
SE424991B (sv) Sett att framstella nya 5-fenyl-oxazolidinoner
SE427655B (sv) Sett att framstella abietamidderivat
SE7509209L (sv) Sett att framstella nya kinolinderivat
SE415252B (sv) Sett att framstella nya oxifenylbutazonderivat
SE412233B (sv) Sett att framstella nya fenotiazinderivat
SE7609666L (sv) Sett att framstella nya 5-aminometyltiazolderivat
SE428471B (sv) Sett att framstella imidazolderivat
SE7505711L (sv) Nya tiofenderivat och sett att framstella desamma
SE7506571L (sv) Sett att framstella nya bufatrienolidramnosideter
SE439303B (sv) Sett att framstella nya aminoetanolderivat

Legal Events

Date Code Title Description
NAL Patent in force

Ref document number: 7502520-5

Format of ref document f/p: F

NUG Patent has lapsed

Ref document number: 7502520-5

Format of ref document f/p: F